Results 131 to 140 of about 22,035 (254)

Use of darunavir in HIV-infected women during pregnancy

Терапевтический архив, 2013
The use of antiretroviral drugs (ARVDs) in a mother and a child can reduce the risk of vertical transmission of human immunodeficiency virus (HIV) to less than 1%; therefore, highly active antiretroviral therapy is used in all pregnant women regardless ...
L Iu Afonina, E E Voronin
doaj  

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir [PDF]

Reactions Weekly, 2020
openaire   +1 more source

Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection

HIV/AIDS: Research and Palliative Care, 2016
Rustin D Crutchley,1 Rakesh C Guduru,2 Amy M Cheng1 1Department of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston, 2CompanionDX, Houston, TX, USA Abstract: Atazanavir/cobicistat (ATV/c) and darunavir/cobicistat (
Crutchley RD, Guduru RC, Cheng AM,
doaj  

Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study

Drug Design, Development and Therapy, 2019
A Antinori,1 S Rusconi,2 N Gianotti,3 T Bini,4 D Mancusi,5 R Termini51HIV/AIDS Department, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, Rome, Italy; 2Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan,
Antinori A, Rusconi S, Gianotti N, Bini T, Mancusi D, Termini R   +5 more
doaj  

Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial. [PDF]

Nat Commun
Català-Moll F, Blázquez-Bondia C, Farré-Badia J, Torres F, Manzardo C, Bonfill E, Curran A, Domingo P, Podzamczer D, Force L, Falcó V, Parera M, Casadellà M, Miró JM, Noguera-Julian M, Paredes R, ADVANZ-4 MISTRAL investigators.   +16 more
europepmc   +1 more source

Reversible Effects of Integrase Inhibitors on Newly Differentiated Adipocytes. [PDF]

Viruses
Pickering RT, Asundi A, Olson A, Soden K, Lin NH.   +4 more
europepmc   +1 more source

Advancements in development of novel class of HIV protease inhibitors. [PDF]

Ann Med
Gu WG, Yin GZ, Zhang YP.
europepmc   +1 more source

Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV. [PDF]

Antimicrob Agents Chemother
Tsirizani L, Waalewijn H, Szubert A, Mulenga V, Chabala C, Bwakura-Dangarembizi M, Chitsamatanga M, Rutebarika DA, Musiime V, Kasozi M, Lugemwa A, McIlleron HM, Burger DM, Gibb DM, Colbers A, Denti P, Wasmann RE, CHAPAS-4 trial team.   +17 more
europepmc   +1 more source

Laser Microinterferometry for API Solubility and Phase Equilibria: Darunavir as a Case Example. [PDF]

Pharmaceutics
Makarova V, Mandrik M, Antonov S.
europepmc   +1 more source

Phenotypic impacts of treatment-selected mutations in HIV-2 protease on darunavir and lopinavir susceptibility: Evaluating genotypic HIV-2 drug resistance tools. [PDF]

PLOS Glob Public Health
Raugi DN, Nixon RS, Smith RA, Hawes SE, Diallo K, Diallo MB, Faye K, Diaw B, Sy MP, Sall F, Seydi M, Gottlieb GS, University of Washington-Senegal HIV-2 Study Group.   +12 more
europepmc   +1 more source